AtaiBeckley set to unlock value from positive depression therapy trial results, says Jefferies

Jefferies flagged Atai’s VLS-01 oral DMT-based therapy as a potential catalyst as the company nears Phase IIb readouts. With Phase IIb enrollment for treatment-resistant depression (TRD) now completed, analysts expect a potential topline data update in Q4 2026 that could act as a de-risking event and add value to Atai’s psychedelic medicine pipeline.

Analysis

The market is likely underestimating how much of ATAI’s value remains a probability-weighted option on a single late-stage readout. For pre-revenue psychedelic developers, the main driver is not near-term sales but whether a program can move from "science project" to a financeable asset; completed enrollment meaningfully reduces execution risk, but it does not yet change the core efficacy/safety uncertainty. In practice, this tends to support a modest rerating into the data window, then a much larger move only if the signal is clean.

The second-order issue is dilution risk. If the company needs to bridge to a 2026 readout, every additional quarter without a strong capital-markup event increases the probability of equity financing, which can cap upside even if sentiment improves. That makes the stock more sensitive to cash runway disclosures than to generic analyst optimism; peers with nearer-term catalysts or stronger balance sheets could capture relative flows if investors decide the sector is re-opening.

Contrarianly, consensus may be treating "completed enrollment" as a de-risking event with more economic value than it deserves. The real inflection is data quality: effect size, tolerability, and dropout versus placebo. If the initial readout is modest or noisy, the multiple can compress quickly because the market will discount both commercial optionality and the platform story; if the readout is strong, the rerating can be outsized given the current base.

Key Decisions for Investors

• No large outright position now; treat ATAI as a catalyst watchlist name until the cash runway and trial integrity are independently verified. Missing data: fully diluted share count, cash burn, and protocol specifics.
• For investors wanting exposure, use a small-sized long-dated call spread in ATAI rather than common stock; the best payoff is if the market starts capitalizing the 2026 readout before financing risk reasserts itself.
• Relative-value idea: long ATAI / short a basket of lower-quality pre-revenue biotech funding proxies or the XBI ETF into periods of biotech risk-on, but only if ATAI trading volume confirms accumulation. This is a sentiment trade, not a fundamentals conviction trade.
• Set a hard risk flag on any financing announcement or runway update; if dilution appears likely within the next 2-3 quarters, the thesis should be reduced regardless of analyst enthusiasm.